^
    Back
    Association details:
    Biomarker:AR positive
    Cancer:Triple Negative Breast Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncologist
    Title:

    A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer

    Published date:
    11/03/2020
    Excerpt:
    This study was an open-label phase II study for AR+ (≥10%, 1+ by IHC) mTNBC. Eligible patients received pembrolizumab 200 mg IV every 3 weeks and enobosarm 18 mg oral daily….The combination of enobosarm and pembrolizumab was well tolerated with a modest clinical benefit rate of 25% at 16 weeks in heavily pretreated AR+ TNBC without pre-selected PD-L1.
    Secondary therapy:
    enobosarm
    DOI:
    10.1002/onco.13583